title: Human lymphoblastoid interferon does not increase survival when added to mitozantrone in the treatment of hepatocellular carcinomas.
abstract: Human lymphoblastoid interferon, in an initial dose of 2.5 MU m-2 weekly i.m., was given with mitozantrone 12 mg m-2 i.v. every 3 weeks to 15 patients with hepatocellular carcinoma. The survival curve for these patients was worse than that of 15 patients previously treated with mitozantrone alone; there were more long-term survivors in those not given interferon; more side-effects were seen in the group given interferon. The addition of interferon to mitozantrone in the management of hepatocellular carcinoma is not recommended.
authors.affiliation: Academic Department of Medicine, Royal Free Hospital and Medical School, London, UK.
authors.forename: M G
authors.initials: MG
authors.lastname: Brook
authors.forename: A A
authors.initials: AA
authors.lastname: Dunk
authors.forename: J A
authors.initials: JA
authors.lastname: McDonald
authors.forename: A M
authors.initials: AM
authors.lastname: Lever
authors.forename: C
authors.initials: C
authors.lastname: Goh
authors.forename: H C
authors.initials: HC
authors.lastname: Thomas
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000401:mortality; D002648:Child; D005260:Female; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage
chemical_list: D016898:Interferon-alpha; D008942:Mitoxantrone